A Phase 1b/2, Open-Label, Multi-Center Study of Tivozanib in Combination With Nivolumab in Subjects With Metastatic Renal Cell Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 08 Jun 2017
At a glance
- Drugs Tivozanib (Primary) ; Nivolumab
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Acronyms TiNivo
- Sponsors AVEO Oncology
- 08 Jun 2017 According to an AVEO Oncology media release, results from phase I portion of this study will be submitted for presentation at an upcoming scientific meeting.
- 08 Jun 2017 According to an AVEO Oncology media release, Phase 1 dose escalation portion of the trial has been completed and this trial has progressed to the Phase 2 portion.
- 04 May 2017 According to an AVEO Oncology media release, the company expects to complete the phase I portion of the study in the first half of 2017.